Patient-Centred Care When Treating Plaque Psoriasis With Secukinumab: Reasons for Discontinuing Treatment Outside of Randomized Controlled Trials

J Cutan Med Surg. 2018 Nov/Dec;22(6):647-649. doi: 10.1177/1203475418782135.

Authors

Jorge R Georgakopoulos¹, Arvin Ighani², Michelle Phung³, Jensen Yeung^{2

4

5

6}

Affiliations

¹ 1 Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
² 2 Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
³ 3 Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
⁴ 4 Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
⁵ 5 Women's College Hospital, Toronto, ON, Canada.
⁶ 6 Probity Medical Research Inc., Waterloo, ON, Canada.

PMID: 30322297
DOI: 10.1177/1203475418782135

No abstract available

Keywords: IL-17A; adverse event; discontinuation; efficacy; plaque psoriasis; secukinumab.

Publication types

Multicenter Study

MeSH terms

Adolescent
Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Female
Humans
Male
Medication Adherence / statistics & numerical data*
Middle Aged
Ontario / epidemiology
Psoriasis / drug therapy*
Retrospective Studies
Young Adult

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
secukinumab